NASDAQ:XERS Xeris Biopharma (XERS) Stock Price, News & Analysis $10.31 +0.24 (+2.38%) Closing price 10/16/2026 04:00 PM EasternExtended Trading$10.27 -0.04 (-0.39%) As of 10/16/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Xeris Biopharma Stock (NASDAQ:XERS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Xeris Biopharma alerts:Sign Up Key Stats Today's Range$9.84▼$10.3350-Day Range$7.45▼$10.4852-Week Range$5.25▼$11.33Volume2.29 million shsAverage Volume3.48 million shsMarket Capitalization$1.88 billionP/E RatioN/ADividend YieldN/APrice Target$13.20Consensus RatingHold Company Overview Xeris Biopharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology, and related rare or chronic conditions. The company uses proprietary formulation technologies designed to deliver medicines that are difficult to formulate or administer through conventional methods, including its XeriSol and XeriJect platforms. Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection used to treat severe hypoglycemia; Keveyis (dichlorphenamide), a treatment for primary periodic paralysis; and Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with Cushing’s syndrome. The company also markets Ogluo, a glucagon autoinjector, in certain markets. Its products are primarily marketed in the United States, with selected international availability supported through commercial partners and regional arrangements. The company was established as Xeris Pharmaceuticals and became a publicly traded company in 2018. In 2021, Xeris completed a combination with Strongbridge Biopharma, expanding its portfolio and adding therapies focused on rare endocrine diseases. In addition to its commercial products, Xeris continues to develop medicines and drug-delivery applications based on its proprietary formulation platforms.AI Generated. May Contain Errors. Read More Xeris Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks87th Percentile Overall ScoreXERS MarketRank™: 4.37136435748 of 5 starsXeris Biopharma scored higher than 87% of companies evaluated by MarketBeat, and ranked 48th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingXeris Biopharma has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialXeris Biopharma has a consensus price target of $13.20, representing about 28.0% upside from its current price of $10.31.Amount of Analyst CoverageXeris Biopharma has only been the subject of 3 research reports in the past 90 days.Read more about Xeris Biopharma's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth328.57% Earnings GrowthEarnings for Xeris Biopharma are expected to grow by 328.57% in the coming year, from $0.07 to $0.30 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xeris Biopharma is -93.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xeris Biopharma is -93.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXeris Biopharma has a P/B Ratio of 128.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Xeris Biopharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.13% of the float of Xeris Biopharma has been sold short.Short Interest Ratio / Days to CoverXeris Biopharma has a short interest ratio ("days to cover") of 1.74, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Xeris Biopharma has recently decreased by 10.63%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXeris Biopharma does not currently pay a dividend.Dividend GrowthXeris Biopharma does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.38 News SentimentXeris Biopharma has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Xeris Biopharma this week, compared to 4 articles on an average week.Search Interest4 people have searched for XERS on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows9 people have added Xeris Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 800% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Xeris Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,202,666.00 in company stock.Percentage Held by Insiders4.35% of the stock of Xeris Biopharma is held by insiders.Percentage Held by Institutions42.75% of the stock of Xeris Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Xeris Biopharma's insider trading history. Receive XERS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XERS Stock News HeadlinesXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Has Average Target Price of $13.20 According to BrokeragesOctober 16 at 2:15 AM | americanbankingnews.comXeris Biopharma Holdings, Inc. Announces Clinical and Scientific Data Presentations in Support of Gvoke, Recorlev, and Investigational Xp-8121 Program At Scientific MeetingsOctober 16 at 2:01 AM | marketscreener.comMFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 18 at 1:00 AM | Weiss Ratings (Ad)Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific MeetingsOctober 16 at 2:01 AM | finance.yahoo.comOrganon & Co. (NYSE:OGN) & Xeris Biopharma (NASDAQ:XERS) Head to Head ReviewOctober 14, 2026 | americanbankingnews.comWhy Xeris Biopharma Holdings (XERS) Is Up 5.8% After Raising 2026 Revenue Guidance And Retiring DebtOctober 8, 2026 | finance.yahoo.comXeris Biopharma (NASDAQ:XERS) Insider Steven Pieper Sells 5,000 Shares of StockOctober 3, 2026 | insidertrades.comInsider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells $250,000.00 in StockSeptember 30, 2026 | insidertrades.comSee More Headlines XERS Stock Analysis - Frequently Asked Questions How have XERS shares performed this year? Xeris Biopharma's stock was trading at $7.85 at the beginning of the year. Since then, XERS shares have increased by 31.3% and is now trading at $10.31. How were Xeris Biopharma's earnings last quarter? Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) issued its earnings results on Thursday, August, 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by $0.19. The firm had revenue of $92.10 million for the quarter, compared to analysts' expectations of $90.13 million. Xeris Biopharma had a positive trailing twelve-month return on equity of 338.21% and a negative net margin of 5.12%. Read the conference call transcript. When did Xeris Biopharma IPO? Xeris Biopharma (XERS) raised $75 million in an IPO on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Mizuho Securities was co-manager. Who are Xeris Biopharma's major shareholders? Top institutional investors of Xeris Biopharma include Vilga Financial Planning LLC (0.58%), Apella Capital LLC (0.11%) and GK Wealth Management LLC. Insiders that own company stock include John Patrick Shannon Jr, Kevin Mcculloch, Steven Pieper, Beth Hecht, John Johnson, Jeffrey W Sherman, Marla Persky, Barbara-Jean A Bormann-Kennedy, Dawn Halkuff and James Aloysius Brady. View institutional ownership trends. How do I buy shares of Xeris Biopharma? Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Xeris Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xeris Biopharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Pfizer (PFE), Sorrento Therapeutics (SRNE), NIO (NIO) and Palantir Technologies (PLTR). Company Calendar Last Earnings8/06/2026Today10/18/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 XERS's financial health is in the Green zone, according to TradeSmith. XERS has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:XERS CIK1867096 Webwww.xerispharma.com Phone(844) 445-5704FaxN/AEmployees435Year FoundedN/APrice Target and Rating Average Price Target for Xeris Biopharma$13.20 High Price Target$18.00 Low Price Target$8.00 Potential Upside/Downside+28.0%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.11) Trailing P/E RatioN/A Forward P/E Ratio147.29 P/E GrowthN/ANet Income$550 thousand Net Margins-5.12% Pretax Margin-5.12% Return on Equity338.21% Return on Assets3.50% Debt Debt-to-Equity Ratio17.00 Current Ratio1.45 Quick Ratio1.02 Sales & Book Value Annual Sales$335.41 million Price / Sales5.60 Cash Flow$0.10 per share Price / Cash Flow102.93 Book Value$0.08 per share Price / Book128.88Miscellaneous Outstanding Shares182,320,000Free Float174,389,000Market Cap$1.88 billion OptionableOptionable Beta0.53 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:XERS) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredDid you grab your copy yet?Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarte...Profits Run | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredThe Claude AI company doubled in value... you missed itIn May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly di...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xeris Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
